Fye K H, Crowley E, Berger T G, LeBoit P E, Connolly M K
Division of Rheumatology, Department of Medicine, University of California, San Francisco, USA.
J Am Acad Dermatol. 2001 Aug;45(2):300-2. doi: 10.1067/mjd.2001.114587.
Sweet's syndrome and related neutrophilic dermatoses have been associated with a variety of medications. Celecoxib is a new cyclo-oxygenase-2 inhibitor recently approved for arthritis. We describe a 57-year-old man who experienced tender pustulopapular lesions on the dorsal aspects of the hands, neck, and legs 1 week after starting celecoxib. Histopathologic examination of the lesion showed a diffuse dermal neutrophilic infiltrate, edema of the papillary dermis, spongiform pustules, and no leukocytoclastic vasculitis. These findings were consistent with Sweet's syndrome. Without realizing a possible association, the patient rechallenged himself with a second course of the medication, which resulted in a rapid exacerbation of his lesions. After discontinuing the medication for the second time, the patient has had complete clearing of his lesions. To our knowledge, this is the first report of Sweet's syndrome associated with this new class of nonsteroidal anti-inflammatory drugs.
斯威特综合征及相关嗜中性皮肤病与多种药物有关。塞来昔布是一种最近被批准用于治疗关节炎的新型环氧化酶 -2 抑制剂。我们报告一例 57 岁男性,在开始服用塞来昔布 1 周后,双手、颈部和腿部背侧出现疼痛性脓疱丘疹性皮损。皮损的组织病理学检查显示真皮弥漫性嗜中性粒细胞浸润、乳头真皮水肿、海绵状脓疱,且无白细胞破碎性血管炎。这些发现符合斯威特综合征。患者未意识到可能的关联,自行再次服用该药,导致皮损迅速加重。第二次停药后,患者皮损完全消退。据我们所知,这是首例与这类新型非甾体抗炎药相关的斯威特综合征报告。